脓毒症与非脓毒症急性肾损伤及终末期肾病患者在连续肾脏替代治疗前后的降钙素原水平
该回顾性队列研究纳入41例需CKRT的危重AKI或ESKD患者,共111次血浆降钙素原检测,按培养结果严格定义脓毒症,比较CKRT前及CKRT第1、2、3天的血浆降钙素原。非脓毒症患者92%(66/72)的血浆降钙素原≥0.5 ng/mL;CKRT前非脓毒症AKI为5.6(1.5-18.9)ng/mL vs 脓毒症AKI 58.1(6.9-195.5)ng/mL(P=0.03),非脓毒症ESKD 3.3(1.2-8.3)ng/mL vs 脓毒症ESKD 3.7(1.4-209.8)ng/mL(P=0.79);ROC曲线分析未找到可靠区分脓毒症与非脓毒症的界值。滤出液降钙素原约为血浆的20%(筛分系数0.2),但CKRT期间血浆降钙素原未显著下降。作者认为肾功能衰竭危重患者应避免检测降钙素原。
要点
- 非脓毒症AKI或ESKD危重患者中92%(66/72)血浆降钙素原≥0.5 ng/mL,0.5 ng/mL这一细菌感染诊断阈值在该人群不适用。
- CKRT前脓毒症AKI降钙素原58.1(6.9-195.5)ng/mL vs 非脓毒症AKI 5.6(1.5-18.9)ng/mL(P=0.03),但两组数值大量重叠,ROC曲线分析无可靠鉴别界值。
- CKRT前脓毒症ESKD降钙素原3.7(1.4-209.8)ng/mL vs 非脓毒症ESKD 3.3(1.2-8.3)ng/mL(P=0.79),无统计学差异。
- CKRT期间滤出液降钙素原约为血浆的20%(筛分系数0.2),提示治疗中有清除,但AKI和ESKD患者血浆降钙素原均未显著下降。
- 作者结论:肾功能衰竭的危重患者应避免检测降钙素原,因结果在该人群缺乏特异性。
适用人群与场景
- 需连续肾脏替代治疗的危重脓毒症或非脓毒症成人患者,合并急性肾损伤(AKI)或终末期肾病(ESKD)。
- CKRT模式为连续静脉-静脉血液透析。
诊断标准与关键阈值
- 脓毒症状态依据培养结果严格定义。
- 0.5 ng/mL为原文献引用的细菌感染很可能诊断阈值,但本研究显示非脓毒症AKI或ESKD患者中92%(66/72)血浆降钙素原≥0.5 ng/mL。
研究设计与关键结果
- 回顾性队列研究,共41例危重脓毒症或非脓毒症AKI或ESKD患者,111次血浆降钙素原检测,在CKRT前及CKRT第1、2、3天测量血浆降钙素原,并在CKRT第1、2、3天测滤出液降钙素原。
- 非脓毒症AKI或ESKD患者中92%(66/72)血浆降钙素原测量值≥0.5 ng/mL。
- CKRT前降钙素原(中位数(IQR),ng/mL):非脓毒症AKI 5.6(1.5-18.9) vs 脓毒症AKI 58.1(6.9-195.5),P=0.03;非脓毒症ESKD 3.3(1.2-8.3) vs 脓毒症ESKD 3.7(1.4-209.8),P=0.79。
- 尽管脓毒症AKI患者降钙素原显著升高,但脓毒症与非脓毒症患者降钙素原水平大量重叠,ROC曲线分析未找到能可靠区分脓毒症与非脓毒症的界值。
- CKRT全程滤出液降钙素原约为血浆水平的20%(筛分系数0.2),提示治疗期间存在清除;但AKI或ESKD患者血浆降钙素原在CKRT期间均未显著下降。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:对肾功能衰竭的危重患者应避免检测降钙素原,因为结果在该人群缺乏特异性。
- 在需CKRT的AKI或ESKD患者中,降钙素原升高不能用于区分脓毒症与非脓毒症状态,CKRT前后均如此。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Procalcitonin is a 14.5 kDa protein used clinically as a marker of sepsis and therapeutic response to antibiotic therapy. However, its utility in critically ill patients with either acute kidney injury (AKI) or end-stage kidney disease (ESKD) who require continuous kidney replacement therapy (CKRT) is unknown. The aim of this study was to determine if plasma levels of procalcitonin could reliably distinguish septic from nonseptic status in patients with AKI or ESKD prior to or during CKRT.
METHODS: Procalcitonin concentrations were measured in plasma of 41 critically ill septic or non-septic subjects with AKI or ESKD prior to CKRT (pre-CKRT) and on days 1, 2, and 3 of CKRT in this retrospective cohort study (n = 111 total plasma measurements). Continuous venovenous hemodialysis was the modality of CKRT in these patients. Sepsis status was stringently defined based on culture results. Effluent procalcitonin levels were ascertained on days 1, 2, and 3 of CKRT to assess the clearance of procalcitonin and effects on plasma levels.
RESULTS: 92% (66/72) of the plasma procalcitonin measurements among nonseptic patients with either AKI or ESKD were ≥ 0.5 ng/mL (the diagnostic threshold beyond which bacterial infection is very likely). Prior to CKRT initiation, procalcitonin levels were (median (IQR), ng/mL) 5.6 (1.5-18.9) in nonseptic AKI and 58.1 (6.9-195.5) in septic AKI (P = 0.03) and were 3.3 (1.2-8.3) in nonseptic ESKD and 3.7 (1.4-209.8) in septic ESKD (P = 0.79). However, despite being significantly elevated in septic patients with AKI, substantial overlap among procalcitonin levels was present and ROC curve analysis found no cut point that could reliably separate septic from nonseptic patients. Effluent procalcitonin levels were consistently ~ 20% of plasma levels throughout the course of CKRT (i.e., sieving coefficient was 0.2) suggesting that clearance occurs during therapy. However, plasma procalcitonin levels did not significantly decline during CKRT in either AKI or ESKD.
CONCLUSION: Procalcitonin levels are markedly elevated in nonseptic critically ill patients with either AKI or ESKD and do not effectively distinguish sepsis from nonseptic status prior to or during CKRT. We conclude that procalcitonin testing should be avoided in critically ill patients with kidney failure since results are nonspecific in this population.
参考来源
- Foulon N, Haeger SM, Okamura K, et al. Procalcitonin levels in septic and nonseptic subjects with AKI and ESKD prior to and during continuous kidney replacement therapy (CKRT). Crit Care. 2025. PMID: 40307866. doi:10.1186/s13054-025-05414-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。